Cell line · CVCL_1543
Papers51
1 to 20 of 51
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Selective elimination of quiescent cancer cells by dequalinium chloride via ROS-mediated ferroptosis. | FEBS Open Bio | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PARP inhibition enhances the antitumor activity of HER3-DXd in non-small cell lung cancer. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting the CHD3 chromatin remodeler exploits a synthetic lethal vulnerability in dual SMARCA4/SMARCA2-deficient cancers via derepression of PARD3B. | NPJ Precis Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A comprehensive functional atlas of ALK kinase domain variants reveals resistance landscape to ALK inhibitors. | Genome Biol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ANP32A-mediated histone 3 K27 acetylation is essential for sotorasib activity in KRAS-mutant non-small cell lung cancer. | J Biol Chem | 2026 | Its Methods give the RRID and name the line | PubMed | |
| LINC01116, a hypoxia-lncRNA marker of pathological lymphangiogenesis and poor prognosis in lung adenocarcinoma. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Utility of CK8/18 in identifying circulating tumor cells derived from lesions in patients with non-small cell lung cancer. | Transl Lung Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Cancer-associated fibroblasts promote drug resistance in ALK-driven lung adenocarcinoma cells by upregulating lipid biosynthesis. | Cancer Metab | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Amplified dosage of the NKX2-1 lineage transcription factor controls its oncogenic role in lung adenocarcinoma. | Mol Cell | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Identification of nonsense-mediated decay inhibitors that alter the tumor immune landscape. | Elife | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Integrative transcriptomic analysis identifies emetine as a promising candidate for overcoming acquired resistance to ALK inhibitors in lung cancer. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Combined blockade of GPX4 and activated EGFR/HER3 bypass pathways inhibits the development of ALK-inhibitor-induced tolerant persister cells in ALK-fusion-positive lung cancer. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Synergy of EGFR and AURKA Inhibitors in KRAS-mutated Non-small Cell Lung Cancers. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Soluble galectin-3 as a microenvironment-relevant immunoregulator with prognostic and predictive value in lung adenocarcinoma. | Mol Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| PubMed 37994369 | bioRxiv | 2023 | Its Methods give the RRID and name the line | PubMed | |
| ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer. | Nat Cancer | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation. | Nat Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
Clinical and prognostic significance of detecting CEA, EGFR, LunX, c-met and EpCAM mRNA-positive cells in the peripheral blood, tumor-draining blood and bone marrow of non-small cell lung cancer patients. | Transl Lung Cancer Res | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Identification of Membrane-expressed CAPRIN-1 as a Novel and Universal Cancer Target, and Generation of a Therapeutic Anti-CAPRIN-1 Antibody TRK-950. | Cancer Res Commun | 2023 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1543/papers